Gardiquimod VacciGrade™

Imidazoquinoline compound

Gardiquimod is an imidazoquinoline compound developed and manufactured by InvivoGen. This imidazoquinoline compound is a guanosine derivative and agonist for TLR7. Gardiquimod™ is an effective adjuvant by activating dendritic cells (DCs) and B cells to induce cytokines optimal for Th1 cell immunity, and antibody production.

Gardiquimod™ VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.

Gardiquimod™ VacciGrade™ is for research use only, not for use in humans.


Specificity: Th1 response
Working concentration: 10- 100 μg/mouse
Quality: Sterile, Endotoxin level <5 EU/mg
CAS number: 1020412-43-4
Solubility: 1 mg/ml in physiological water
Quality control
Gardiquimod™ VacciGrade™ is a preclinical grade preparation of Gardiquimod™ . It is prepared under strict aseptic conditions and is tested for the presence of endotoxins. Gardiquimod™ VacciGrade™ is guaranteed sterile and its endotoxin level is <5 EU/mg.


• 5 mg of sterile lyophilized Gardiquimod VacciGrade™
• 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)

Gardiquimod VacciGrade™ is shipped at room temperature and should be stored at -20°C. Lyophilized product is stable for 1 year when properly stored. Upon resuspension, prepare aliquots of Gardiiquimod VacciGrade™ and store at -20°C. Resuspended product is stable for 6 months when properly stored. Avoid repeated freeze-thaw cycles.


Gardiquimod™ is a imidazoquinoline compound developed and manufactured by InvivoGen. Similarly to Imiquimod, Gardiquimod™ induces the activation of NF-κB in HEK293 cells expressing human or mouse TLR7. In vitro models of vaccination indicate that Gardiquimod™ is a strong immunostimulant inducing cytokine production and the generation of dendritic cells [1].

Experimental models demonstrated that Gardiquimod™ can induce strong cellular responses and has potential as an adjuvant for cancer therapy [2, 3]. Furthermore, Gardiquimod™ can induce mucosal responses that are superior to R848 and comparable to those induced by the established mucosal adjuvant cholera toxin [4].

1. Ma Y et al., 2007. In vitro vaccination site: a novel test bed for immunopotentiators. J Immunol. 178, S18.
2 Ma F. et al., 2010. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cellular & Molecular Immunology 7, 381-388.
3. Cho HI & Celis E., 2009. Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor Effects. Cancer Res. 69(23):9012-9. 4. Velasquez LS. et al., 2010. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin Vaccine Immunol. 17(12):1850-8.


Gardiquimod VacciGrade™

Description Imidazoquinoline compound -TLR7 agonist
Cat. Codevac-gdq
Unit Size5 mg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".